Chemotherapy with mitomycin-C, epidoxorubicin and vinblastine in CMF failing breast cancer patients.
Since most patients with breast cancer are treated with CMF as first line chemotherapy (usually in the adjuvant setting), schedules with alternative drugs are needed for the metastatic disease. In this study a new combination of Mitomycin, Epidoxorubicin and Vinblastine was employed in a group of 24 patients with metastatic breast cancer. A response rate of 37.5% was observed with a mild to moderate toxicity.
Pronzato
P
P
Department of Medical Oncology, Istituto Nazionale per la Riecerca sul Cancro, Genova, Italy.
Amoroso
D
D
Bertelli
G
G
Queirolo
P
P
Sertoli
M R
MR
Rosso
R
R
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D003520:Cyclophosphamide / Q000008:administration & dosage; D015251:Epirubicin / Q000008:administration & dosage; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D008727:Methotrexate / Q000008:administration & dosage; D008875:Middle Aged; D016685:Mitomycin; D008937:Mitomycins / Q000008:administration & dosage; D009362:Neoplasm Metastasis; D009367:Neoplasm Staging; D014747:Vinblastine / Q000008:administration & dosage
D008937:Mitomycins; D015251:Epirubicin; D016685:Mitomycin; D014747:Vinblastine; D003520:Cyclophosphamide; D005472:Fluorouracil; D008727:Methotrexate